Actinium to Host KOL Webinar to Discuss Iomab-ACT Commercial CAR T-Cell Therapy Trial Design, Objectives and Potential Market Opportunity

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs)...

PR NewswireMay 15 08:30 ET

Reported Earlier, Actinium To Present Improved Survival Outcomes In TP53 Positive Patients At The EHA 2024 and Long-Term Efficacy Results In Older Patients Receiving An Iomab-B Led Bone Marrow Transplant In The Phase 3 SIERRA Trial

- Median Overall Survival of 5.49 months observed in patients with a TP53 mutation receiving an Iomab-B led allogeneic bone marrow transplant compared to 1.66 months in patients that did not receive I

BenzingaMay 15 03:11 ET

Actinium : Iomab-B Phase 3 Trial Results Show Significant Survival Benefit In High-Risk AML Patients

RTTNewsMay 14 22:38 ET

Actinium Announces Oral Presentation Detailing Improved Survival Outcomes in TP53 Positive Patients at the EHA 2024 Annual Congress and Presentation of Long-Term Efficacy Results in Older Patients Receiving an Iomab-B Led Bone Marrow Transplant in the...

Actinium Announces Oral Presentation Detailing Improved Survival Outcomes in TP53 Positive Patients at the EHA 2024 Annual Congress and Presentation of Long-Term Efficacy Results in Older Patients Rec

PR NewswireMay 14 18:38 ET

NYSE American New 52-Week Highs And Lows

New Highs 5 COMPANY SYMBOL HIGH VOLUME ------- ------ ---- ------ Actinium Pharmaceuticals ATNM 9.99 307,312 Am

Dow JonesMay 14 11:20 ET

Express News | Actinium Pharmaceuticals Inc : Stephens Initiates Coverage With Overweight Rating; Price Target $25

ReutersMay 14 06:31 ET